Matrixyl and signal peptides: what the skin trials show

From procollagen to the bottle: the origin of KTTKS

The story of signal peptides begins in a laboratory at the University of Tennessee in Memphis. Katayama's group had already shown that a subfragment of the carboxy-terminal propeptide of type I collagen (residues 197–241) markedly increased extracellular matrix production in fibroblasts. In 1993 they dissected that fragment and found that the pentapeptide Lys-Thr-Thr-Lys-Ser (KTTKS, residues 212–216) was the minimum sequence needed for potent stimulation of collagen and fibronectin production in a variety of mesenchymal cells¹. The authors proposed that matrix synthesis is subject to positive or negative feedback depending on the proteases present during tissue regeneration¹.

The leap to cosmetics came from attaching a palmitic acid to KTTKS: the result, palmitoyl pentapeptide-4 or pal-KTTKS, is the amphiphilic peptide sold under the trade name Matrixyl⁴. Dermatology reviews group cosmetic peptides into three main categories: signal, neurotransmitter-affecting and carrier peptides³. The families are summarized in SNAP-8 and argireline: "topical Botox" under the microscope; here we go deeper into the first.

Matrikines: how the matrix talks to the fibroblast

The conceptual framework is that of matrikines. Connective tissue cells respond not only to hormones, cytokines and growth factors: when they degrade matrix proteins they release peptides that become new signals for neighboring cells, so a true regulatory loop exists. The term "matrikine" was proposed for these matrix-derived peptides able to regulate cell activity; the tripeptide GHK is one of the examples studied by the Reims group². The logic of a topical signal peptide is to mimic that "damaged matrix, time to rebuild" message.

In human dermal and corneal fibroblasts, C16-KTTKS stimulated collagen production in a concentration-dependent manner, close to its critical aggregation concentration, suggesting that its self-assembly into nanotapes and its biological activity are related⁴. GHK, the other classic matrikine, is covered in GHK-Cu: the mechanism of action, step by step.

The Matrixyl family: what each version contains

• Palmitoyl pentapeptide-4 (pal-KTTKS, Matrixyl): formula C39H75N7O10, 802.1 g/mol⁷; the molecule with the most clinical data⁹¹⁰¹¹.
• Palmitoyl tripeptide-1 (pal-GHK) and palmitoyl tetrapeptide-7 (pal-GQPR): the two peptides present in Matrixyl 3000¹³. The first is the lipophilic version of GHK, the copper-carrier peptide described on the GHK-Cu data sheet.
• Palmitoyl tripeptide-38: described as a "matrix-repair" tripeptide; its published human data come from an open-label study of a combination serum¹⁴.

The vehicle-controlled trials, one by one

Pal-KTTKS alone. The reference study is Robinson and colleagues': 93 Caucasian women aged 35 to 55, a 12-week, double-blind, placebo-controlled, left-right randomized split-face trial. A moisturizer with 3 ppm pal-KTTKS was compared with the same moisturizer without the peptide; the peptide was well tolerated and significantly improved wrinkles and fine lines vs control by both quantitative technical analysis and expert image grading, and participants also perceived the improvement⁹.

Pal-KTTKS in combination. Two double-blind, randomized, split-face trials (n = 42 and n = 35) in women aged 30 to 70 with moderate periorbital wrinkles tested products containing niacinamide, pal-KT, pal-KTTKS and carnosine twice daily for 4 weeks. Measured by 3D optical topometry (FOITS), periorbital roughness improved vs the untreated side, and a meta-analysis of both studies confirmed improvement in the Ra and Rz parameters¹⁰.

The Matrixyl 3000 components. The Manchester trial is one of the few with long follow-up and biopsies. A product containing palmitoyl oligopeptide, palmitoyl tetrapeptide-7, retinyl palmitate and plant extracts was compared with its identical vehicle in 60 photoaged subjects (30 vs 30) for 6 months, followed by 6 open-label months¹². At 6 months, 43% of the active group improved their wrinkles vs 22% on vehicle (between-group difference not significant, P = 0.10); at 12 months, 70% vs 33% projected for vehicle (P = 0.026). In biopsies, fibrillin-1 increased with the product (2.57 vs 1.84; P = 0.019)¹².

Against tretinoin: the comparative trial

Tretinoin is the prescription benchmark for fine wrinkles, but tolerance problems can affect adherence¹¹. Fu and colleagues randomized 196 women with moderate to moderately severe periorbital wrinkles: 99 used a cosmetic regimen (SPF 30 lotion with 5% niacinamide, peptides and antioxidants; a cream with niacinamide and peptides; and a wrinkle treatment with niacinamide, peptides and 0.3% retinyl propionate) and 97 used 0.02% tretinoin with SPF 30 sunscreen. Every product in the cosmetic regimen contained pal-KT and pal-KTTKS¹¹.

At 8 weeks, the cosmetic regimen significantly improved wrinkle appearance relative to tretinoin; in the 25-participant cohorts that continued for 16 more weeks, the benefits were comparable at 24 weeks. The cosmetic regimen was significantly better tolerated through the first 8 weeks by every measure: erythema, dryness, self-assessment and barrier function¹¹. The authors concluded that an appropriately designed cosmetic regimen can improve wrinkles comparably to the benchmark treatment, with better tolerability¹¹. The key nuance: a multi-active regimen including a low-potency retinoid was tested, not the peptide alone.

The 500 Da barrier and how to get around it

Bos and Meinardi proposed that a compound must weigh less than 500 Da to cross the stratum corneum⁶. Pal-KTTKS weighs 802.1 g/mol⁷, yet palmitoylation changes the picture: KTTKS is highly hydrophilic (logP −1.6), while the logP of pal-KTTKS was calculated at about 3.7⁵. In hairless mouse skin, KTTKS was not detected in any layer, whereas pal-KTTKS appeared in all of them: 4.2 µg/cm² in the stratum corneum, 2.8 µg/cm² in the epidermis and 0.3 µg/cm² in the dermis; neither crossed full-thickness skin into the receptor fluid, meaning the deposit stays in the skin⁸. Palmitoylation also made the peptide more stable against skin proteases⁸.

In three healthy volunteers, OrbiSIMS spectrometry detected pal-GHK and pal-GQPR from a Matrixyl 3000 serum in every layer of the stratum corneum, with a route along the outer surfaces of the cells rather than through them¹³. To go deeper there are two strategies with data: microneedles, which in ex vivo full-thickness human skin increased the signal of pal-KTTKS and other labeled peptides 2- to 22-fold¹⁵; phosphatidylcholine liposomes (under 100 to 200 nm), with which pal-KTTKS stimulated more collagen in fibroblasts than the free peptide and than the 1 mM ascorbic acid positive control¹⁶.

Tolerability: the practical advantage

Tolerance is where signal peptides make their strongest case. In the 93-woman trial pal-KTTKS was well tolerated⁹; in the head-to-head comparison, the peptide regimen beat tretinoin on every tolerance measure¹¹; and a 2026 meta-analysis of 19 randomized trials with 1,341 participants (oral and topical peptides) found them well tolerated, with minimal adverse events¹⁸. In a bioinformatic safety framework, palmitoyl pentapeptide-4 showed sequence homology with matrix proteins (collagen, elastin, fibronectin) without the toxicity signals the framework did flag in toxins such as amanitin¹⁹. For the patient who cannot tolerate retinoids, or as a maintenance base between procedures, it is a profile that is hard to match.

Where the evidence ends

• A 2019 systematic review found 15 clinical studies of matrix-stimulating peptides: only 6 used a placebo control, 5 were double-blind and 9 enrolled only women¹⁷.
• Most key trials have industry funding or authors: Procter & Gamble⁹¹⁰¹¹, Alliance Boots, which funded the Manchester trial¹², and brand consultants in the palmitoyl tripeptide-38 study¹⁴.
• Several trials test blends with niacinamide or retinoids, so they do not isolate the peptide's effect¹⁰¹¹¹².
• In the 2026 meta-analysis, the pooled effect on wrinkles was modest and driven mainly by oral peptides¹⁸.
• The finest penetration data come from mouse or ex vivo skin, and the liposome and microneedle strategies do not yet have comparative clinical trials with pal-KTTKS⁸¹⁵¹⁶.

Taken together, pal-KTTKS has what few cosmeceuticals can show: an identified biochemical origin¹, a 93-participant vehicle-controlled trial⁹ and a comparative trial against the prescription benchmark¹¹. The physician who knows these data can explain to the patient what to expect from a signal peptide and where it fits alongside procedures.